When Smith launched OpenBiome, the entire landscape of CDI treatment changed. Now that he is at Finch Therapeutics, Smith is ready to change the treatment landscapes of many more diseases. “If we could manage this ecosystem and intentionally modulate the composition of this community,” he declares, “we could radically impact the drivers of morbidity and mortality.”
‘Meanwhile, the success of the study in Arizona has prompted America’s Food and Drug Administration (FDA) to look into the matter. A firm called Finch Therapeutics Group, based in Massachusetts, hopes to commercialise the use of MTT as a treatment for autism and the FDA has now granted this effort “fast track” status, which should speed up the review process.’
“Over the past decade, tens of thousands of Americans with C. diff have been cured through fecal transplants, often with a single dose that can bring patients back from the brink of death. The treatment has more than an 80 percent success rate, according to severalstudies, and many patients feel better within hours of receiving the procedure, which is usually administered through colonoscopy or capsules containing desiccated fecal matter.”
CEO Mark Smith describes the vast potential of the microbiome and Finch’s therapeutic platforms:
“We think the microbiome is really fundamental to many aspects of who we are, how our immune systems function, how we regulate our metabolism and how we think and feel,’ says Smith, who predicts ‘broad potential across a number of therapeutic areas.”
Finch Therapeutics Inc. is developing an oral alternative to fecal microbial transplant that it believes entails less biology risk than more advanced oral candidates, with more targeted delivery than full microbiome transplants delivered via enema.
Takeda is paying Finch Therapeutics $10 million upfront for exclusive, global rights to develop and commercialize the latter’s inflammatory bowel disease (IBD) candidate, FIN-524, together with rights to follow-on products for IBD indications.
Back when Mark Smith was working on his PhD at MIT about 6 years ago, his girlfriend’s cousin was infected with C.diff. After 7 reoccurrences following treatment with vancomycin, though, the cousin finally beat it by getting a fecal transplant, with his roommate as the donor.
On June 13, FDA reported that an immunocompromised patient treated with FMT died from a drug resistant infection. Importantly, this patient was not treated by Finch or our collaborator, OpenBiome. The FDA has communicated new mandatory screening standards, which Finch already exceeds. As a result, there is no impact on Finch’s work and our PRISM 3 and PRISM-EXT studies continue uninterrupted.
The infection occurred in a high-risk patient that received material from a donor that was not screened for a common drug resistant pathogen, resulting in exposure and subsequent infection. Finch has a thorough screening program which incorporates a panel of 30+ laboratory tests, including the agent associated with this adverse event, as part of our commitment to patient safety.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its Full-Spectrum Microbiota® (FSM®) therapy for the treatment of children with Autism Spectrum Disorder (ASD). Fast Track designation is intended to facilitate development and expedite review of therapies designed to treat serious conditions and fill an unmet medical need.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to investigational drug CP101 for the treatment of patients with recurrent Clostridium difficile (C. difficile) infection.
Finch Therapeutics Group, Inc. (Finch), a clinical-stage microbiome therapeutics company, announced today that the U.S. Patent and Trademark Office (USPTO) has issued six new patents to Finch covering its Full-Spectrum Microbiota (FSM) and Rationally-Selected Microbiota (RSM) product platforms.
Finch Therapeutics Group, Inc. (Finch), a clinical-stage microbiome therapeutics company, announced today that it has appointed Ulrich Thienel, Ph.D., M.D., as Chief Medical Officer and Gregory Perry as Chief Financial Officer.
Finch Therapeutics Group, Inc. (Finch), a privately held microbiome therapeutics company, announced today the successful close of an oversubscribed $36 million Series B financing, bringing the total capital raised since the Company’s launch to $77 million.
The new entity, Finch Therapeutics Group, combines Crestovo’s extensive IP assets and late-stage candidate for recurrent C. difficile infections, CP101, an oral Full-Spectrum Microbiota product, with Finch’s commercial-scale manufacturing capabilities, discovery platform for developing Rationally-Selected Microbiota therapies and significant product pipeline.
Under the terms of the agreement, Takeda will make an upfront payment of $10 million to Finch for the exclusive worldwide rights to develop and commercialize FIN-524 and rights to follow-on products in IBD. Finch will be eligible for development, regulatory and commercial financial milestones and tiered royalties on worldwide net sales.
Finch Therapeutics, Inc., a microbiome therapeutics company, and OpenBiome, a leading public stool bank, today announced a collaboration to develop FIN-403, an orally administered microbial therapy for approval by U.S. Food and Drug Administration (FDA) in recurrent C. difficile infections.
he Phloral technology will enable the first-in-human discovery approach at Finch. "Phloral is an exciting technology for our research into the microbiome because it enables oral delivery of communities with the same precise targeting as traditional but less convenient colonoscopic delivery,” says Dean Glettig, Director of Product Development at Finch.